Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Phase 3 Completed 42 enrolled North Eastern German Society of Gynaecological Oncology Clovis Oncology, Inc. · collab Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary in first line therapy.

Timeline

Start: 2020-06-08
Primary completion: 2023-12-01
Completion: 2024-07-01

Publications

Malhan D, Hesse J, Nelson N, Stankov K, Nguyen J, Aboumanify O, Garmshausen J, Rogmans G, Czogalla B, Gerber J, Koch M, Kupec T, Tome O, Witteler R, Deryal M, Eichbaum M, Sehouli J, Braicu EI, Relogio A. Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects. EBioMedicine. 2025 Jul;117:105764. doi: 10.1016/j.ebiom.2025.105764. Epub 2025 May 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rucaparib	Small molecule	600 mg	Oral

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Summary

Timeline

Publications

Drugs

Indications